SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

被引：0
|
作者：
Di Maio, D. [1 ]
Liu, C. [1 ]
Marcelli, G. [1 ]
Alvarez, Sanchez J. [1 ]
Overell, J. [1 ]
机构：
[1] F Hoffman La Roche Ltd, Basel, Switzerland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND47
引用
收藏
页码：S631 / S631
页数：1
相关论文
共 50 条
  • [31] Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis
    Hauser, S.
    Kappos, L.
    Montalban, X.
    Craveiro, L.
    Hughes, R.
    McNamara, J.
    Pradhan, A.
    Wormser, D.
    Koendgen, H.
    Wolinsky, J. S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [32] B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis
    Hauser, S.
    Strauli, N.
    Raievska, A.
    Harp, C.
    Koendgen, H.
    Kletzl, H.
    Bonati, U.
    Jia, X.
    Herman, A.
    Kappos, L.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 44 - 45
  • [33] B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis
    Hauser, Stephen
    Strauli, Nicolas
    Raievska, Anastasiia
    Harp, Christopher
    Koendgen, Harold
    Kletzl, Heidemarie
    Bonati, Ulrike
    Jia, Xiaoming
    Herman, Ann
    Kappos, Ludwig
    Bar-Or, Amit
    NEUROLOGY, 2021, 96 (15)
  • [34] Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis REPLY
    Hauser, Stephen L.
    Belachew, Shibeshih
    Kappos, Ludwig
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1694 - 1694
  • [35] Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis
    Osherov, Michael
    Milo, Ron
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) : 1037 - 1047
  • [36] Clinical and economic evaluation of alemtuzumab compared to ocrelizumab in the treatment of relapsing forms of multiple sclerosis in the United States: a payer perspective
    Chirikov, V.
    Ma, I.
    Joshi, N.
    Patel, D.
    Smith, A.
    Giambrone, C.
    Cornelio, N.
    Hashemi, L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 885 - 885
  • [37] Comparison of early treatment response of ocrelizumab in relapsing and progressive multiple sclerosis patients on the basis of cognitive functions
    Ozakbas, S.
    Ozcelik, S.
    Kaya, E.
    Ozdogar, A. T.
    Sagici, O.
    Baba, C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 276 - 276
  • [38] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [39] OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN
    Ayati, N.
    Ma, Sahraian
    Taheri, S.
    Nikfar, S.
    VALUE IN HEALTH, 2019, 22 : S744 - S745
  • [40] Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
    Hussein Algahtani
    Bader Shirah
    Abdulhadi Alqahtani
    Nawal Abdelghaffar
    Samiah Makki
    Acta Neurologica Belgica, 2024, 124 : 303 - 306
12345